HCA(US:HCA)2025-10-24 11:16Financial Performance - Revenues for Q3 2025 increased by 9.6% to $19.161 billion compared to Q3 2024[3] - Net income attributable to HCA Healthcare, Inc. rose by 29.4% to $1.643 billion, or $6.96 per diluted share[3] - Adjusted EBITDA for Q3 2025 increased by 18.5% to $3.870 billion[2] - Revenues for Q3 2025 reached $19,161 million, a 9.6% increase from $17,487 million in Q3 2024[19] - Net income attributable to HCA Healthcare, Inc. for Q3 2025 was $1,643 million, up 29.3% from $1,270 million in Q3 2024[19] - Diluted earnings per share for Q3 2025 increased to $6.96, compared to $4.88 in Q3 2024, representing a 42.7% growth[19] - For the nine months ended September 30, 2025, revenues totaled $56,087 million, a 7.3% increase from $52,318 million in the same period of 2024[20] - Net income for the nine months ended September 30, 2025, was $5,619 million, reflecting a 13.0% increase from $4,971 million in 2024[23] - HCA Healthcare, Inc. experienced a comprehensive income of $4,976 million for the nine months ended September 30, 2025, up from $4,369 million in 2024[20] Cash Flow and Assets - Cash flows from operating activities totaled $4.416 billion, up from $3.515 billion in Q3 2024[7] - Cash and cash equivalents at the end of Q3 2025 were $997 million, down from $2,888 million at the end of Q3 2024[23] - Total assets as of September 30, 2025, amounted to $59,747 million, compared to $59,513 million at the end of 2024[22] - The company reported a net cash provided by operating activities of $10,277 million for the nine months ended September 30, 2025, compared to $7,955 million in 2024[23] Guidance and Forecast - The company updated its 2025 revenue guidance to a range of $75.000 to $76.500 billion[12] - The revised net income guidance for 2025 is now $6.495 to $6.715 billion[12] - For the year ending December 31, 2025, the company forecasts revenues between $75,000 million and $76,500 million[32] - The forecasted net income attributable to HCA Healthcare, Inc. for 2025 is projected to be between $6,495 million and $6,715 million[32] Operational Metrics - Same facility admissions increased by 2.1% and same facility equivalent admissions increased by 2.4% in Q3 2025[5] - Total admissions increased by 2.8% to 577,804 in Q3 2025 from 562,100 in Q3 2024[25] - Revenue per equivalent admission rose to $18,446 in Q3 2025, a 6.1% increase from $17,381 in Q3 2024[25] - The average length of stay decreased to 4.660 days in Q3 2025 from 4.787 days in Q3 2024[25] - The number of hospitals increased to 191 in Q3 2025, up from 187 in Q3 2024[25] Shareholder Returns - The company repurchased 6.514 million shares at a cost of $2.498 billion during Q3 2025[8] - A quarterly cash dividend of $0.72 per share was declared, payable on December 29, 2025[9] Debt and Capital Expenditures - Long-term debt, less debt issuance costs, was $38,401 million as of September 30, 2025, slightly down from $38,333 million at the end of 2024[22] - Capital expenditures for 2025, excluding acquisitions, are estimated to be approximately $5.0 billion[12] - Adjusted EBITDA margin improved to 20.2% in Q3 2025 from 18.7% in Q3 2024[28]